PRESS

Case of Hormone-Positive Breast Cancer Recurrence after 41 Years, with Literature Review on Breast Cancer Management Evolution

Stuti M Trivedi*; Rene R Rubin

   Breast cancer has the highest chances of recurring within the first five years after initial treatment. Recurrence beyond this period, known as late recurrence, which is more common in women with high lymph node involvement, large tumor size, triple-negative tumors, and estrogen receptor-positive tumors. We present


Multifocal Invasive Encapsulated Follicular Variant of Papillary Thyroid Carcinoma with BRAFK601E Mutation: Case Report and Literature Review

Stephanie Marisca; Agnes Stephanie Harahap*; Maria Francisca Ham; Jennifer Jesse Limanto

   The v-raf murine sarcoma viral oncogene homolog B1 (BRAF) mutation is a genetic disorder that generally associated with Papillary Thyroid Cancer (PTC). The BRAFV600E mutation is the most common, while other BRAF mutations like BRAFK601E accounted for less than 1% of cases.


Associated Toxicity in Immunosuppressed Patients with Enfortumab Vedotin - An Essential Differential Diagnosis - Case Report

Joana Gonçalves*; Inês Ângelo; João Gramaça; Idília Pina

   Enfortumab vedotin is an Antibody-Drug Conjugate (ADC) used to treat urothelial cancer. It has recently been associated with reports of Stevens Johnson syndrome/Toxic Epidermal Necrolysis (TEN). I report the clinical case of a 74-year-old man who developed an extensive skin lesion, clinically mimicking TEN.


Molecular Insights of Exonal Polymorphism in Cancer Risk

Rashmi Kumari; Siya Ram; M M A Rizvi; Madhu Rani*

   Single nucleotide polymorphisms are a sort of genetic variations, have been identified in numerous genes that linked to various cancer types. SNPs in exon regions of hub cellular of genes that influence gene expression


Metastatic Sacral Chordoma - A Case Report Unveiling the Achievements and Progress in Recent Management Strategies

Ezhil Sindhanai M Parvath*; Rajesh Balakrishnan*; Selvamani Backianathan; Patricia Sebastian; Raju Titus Chacko; Rima S

    Chordomas are rare tumors that grow slowly, tend to recur locally and seldom metastasize. They originate from residual primitive notochordal tissues along the axial skeleton and are typically found in the sacrococcygeal region (50%), clivus (35%), and vertebral bodies (15%). The median reported survival is 6.29 years with a 10-year survival rate of 39.9%.


MedDocs Publishers

We always work towards offering the best to you. For any queries, please feel free to get in touch with us. Also you may post your valuable feedback after reading our journals, ebooks and after visiting our conferences.